A woman receives a shot of the Johnson & Johnson Covid-19 vaccine at a pop-up vaccination center on the beach in South Beach, Florida on May 9, 2021.

Eva Marie Uzcategui | AFP | Getty Images

The temporary suspension of Johnson & Johnson’s Covid-19 vaccine due to a rare blood clotting problem has not disrupted the U.S. vaccine rollout, White House chief medical officer Dr. Anthony Fauci, the Legislators at a Senate hearing on Tuesday.

U.S. health officials urged states to stop using J & J’s gunshots in April after six women, ages 18 to 48, developed potentially life-threatening blood clots that could lead to stroke.

Some people said the regulatory hiatus seemed to increase vaccine hesitation in the US, especially among people who had not yet been vaccinated.

“I don’t think it was a setback, and if so, we’ve certainly recovered from it,” Fauci said at a pandemic hearing.

Many people prefer the one-shot vaccine over Moderna and Pfizer, which both require two doses about a month apart, Fauci said. He also said the hiatus on the Johnson & Johnson vaccine underscores how seriously the government takes safety.

“The FDA and CDC looked at the data and wanted to see if there were any more. They wanted to let the doctors who might be out there know about the right treatment,” Fauci said. “In the long run, by and large, I don’t think it was a setback. I think it really underscored how seriously we all take safety,” said Fauci.